VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
VelosBio is developing novel antibody-drug conjugates (“ADCs”) to treat haematological cancers and solid tumours.
VelosBio was founded in 2017. The company is headquartered in San Diego, California, with offices in San Francisco and Seattle, Washington.
VelosBio has developed its first ADC linking a humanized anti-ROR1 monoclonal antibody to the cytotoxin, monomethyl auristatin E (MMAE). This lead investigational drug, VLS-101, has demonstrated positive preclinical results in tumor models and currently is being evaluated in a Phase 1, first-in-human, dose-escalation and cohort-expansion study in patients with hematologic malignancies.
VelosBio is backed by Matrix Capital Management, Surveyor Capital, Sofinnova Ventures, Takeda Ventures, Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company and others. The company raised $137M in Series B round on Jul 08, 2020. This brings VelosBio's total funding to $202.7M to date.